Hypofibrinogenemia caused by tigecycline use in a patient with acute cholecystitis: a case report and review of the literature

Yıl 2021, Cilt: 7 Sayı: 6, 667 - 671, 04.11.2021

Müge Ayhan Ferda Can Selma Karaahmetoğlu Rahmet Güner

https://doi.org/10.18621/eurj.693536

Cited By: 1

Öz

Tigecycline is the first member of glicylcycline class of antibiotics, which has a broad spectrum of action. In previous reports, coagulopathy and hypofibrinogenemia caused by tigecycline use was described. We aimed to present a case of hypofibrinogenemia in association with tigecycline use. A 79-years-old male was admitted to medical intensive care unit for acute cholecystitis and acute renal failure. He had no history of coagulation disorder. He was receiving meropenem for septic shock on the admission. On the 7th day of meropenem, his infection didn’t improve and fever continued. Because of that tigecycline was added to treatment. Patient’s infection parameters improved, his fever dropped under treatment, but his prothrombin time, international normalized ratio and activated partial thromboplastin time levels increased and fibrinogen level decreased (0.96 g/L). Tigecycline was discontinued that day. On the fifth day after cessasion of tigecycline, his fibrinogen levels and other coagulation parameters returned to normal ranges. The mechanisms of coagulopathy and hypofibrinogenemia should be elucidated in futher studies. We strictly suggest, regular monitoring of coagulation parameters in patients receiving tigecycline treatment.

Anahtar Kelimeler

tigecycline, hypofibrinogenemia, adverse effect, coagulopathy

Kaynakça

• 1. Wu PC, Wu CC. Tigecycline-associated hypofibrinogenemia: a case report and review of the literature. IDCases 2018;11:56-7.
• 2. Cui N, Cai H, Li Z, Lu Y, Wang G, Lu A. Tigecycline-induced coagulopathy: a literature review. Int J Clin Pharm 2019;41:1408-13.
• 3. Wu X, Zhao P, Dong L, Zhang X. A case report of patient with severe acute cholangitis with tigecycline treatment causing coagulopathy and hypofibrinogenemia. Med (United States) 2017;96:2016-8.
• 4. Zhang Q, Zhou S, Zhou J. Tigecycline treatment causes a decrease in fibrinogen levels. Antimicrob Agents Chemother 2015;59:1650-5.
• 5. Zhang J, Yu L, Fu Y, Zhao Y, Wang Y, Zhao J, et al. Tigecycline in combination with other antibiotics against clinical isolates of carbapenem-resistant klebsiella pneumoniae in vitro. Ann Palliat Med 2019;8:522-631.
• 6. Routsi C, Kokkoris S, Douka E, Ekonomidou F, Karaiskos I, Giamarellou H. High-dose tigecycline-associated alterations in coagulation parameters in critically ill patients with severe infections. Int J Antimicrob Agents 2015;45:90-3.
• 7. Sabanis N, Paschou E, Gavriilaki E, Kalaitzoglou A, Vasileiou S. Hypofibrinogenemia induced by tigecycline: a potentially life-threatening coagulation disorder. Infect Dis (Lond) 2015;47:743-6.
• 8. Pieringer H, Schmekal B, Biesenbach G, Pohanka E. Severe coagulation disorder with hypofibrinogenemia associated with the use of tigecycline. Ann Hematol 2010;89:1063-4.
• 9. Rossitto G, Piano S, Rosi S, Simioni P, Angeli P. Life-threatening coagulopathy and hypofibrinogenaemia induced by tigecycline in a patient with advanced liver cirrhosis. Eur J Gastroenterol Hepatol 2014;26:681-4.
• 10. Yılmaz Duran F, Yıldırım H, Şen EM. A lesser known side effect of tigecycline: hypofibrinogenemia. Turkish J Hematol 2018;35:83-4.